臨床泌尿器科73巻10号

2019年09月発行

特集 腎移植臨床の進歩―集学的治療における泌尿器科医の役割を再考する

〈免疫抑制〉

腎移植免疫抑制療法における新しい展開―エベロリムスの導入とCNI/ステロイドの最小化

著者： 今村亮一¹ 野々村祝夫¹

所属機関： ¹大阪大学大学院医学系研究科器官制御外科学講座（泌尿器科学）

ページ範囲：P.726 - P.731

文献概要

▶ポイント

・エベロリムスは免疫学的側面だけでなく，非免疫学的側面からも生存率・生着率を改善する可能性がある．

・エベロリムスを導入することで，CNIやステロイドの減量ができる可能性が高い．

・ステロイドの最小化に関しては，再発性腎炎や術前の内服歴を十分に念頭に置いて施行すべきである．

参考文献

1） Takahashi K, Uchida K, Yoshimura N, et al : Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients : 12-month results. Transplant Res 2 : 14, 2013

2） Budde K, Becker T, Arns W, et al : Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants : an open-label, randomised, controlled trial. Lancet 377 : 837-847, 2011

3） Eisenberger U, Budde K, Lehner F, et al : Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus : an analysis from the randomized ZEUS study. BMC Nephrol 2 : 154, 2018

4） Pascual J, Berger SP, Witzke O, et al : Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol 29 : 1979-1991, 2018

5） Berger SP, Sommerer C, Witzke O, et al : Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from TRANSFORM study. Am J Transplant, 2019 ［Epub ahead of print］

6） Ying T, Wong G, Lim WH, et al : Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients : A Registry-based 10-year Follow-up of 5 Randomized Trials. Transplantation 103 : 1705-1713, 2019

7） Bemelman FJ, de Fijter JW, Kers J, et al : Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function : The Randomized-Controlled MECANO Trial. Am J Transplant 17 : 1020-1030, 2017

8） Paoletti E, Marsano L, Bellino D, et al : Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients : a 1 year, randomized, controlled trial. Transplantation 93 : 503-508, 2012

9） Murbraech K, Massey R, Undset LH, et al : Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clin Transplant 29 : 678-684, 2015

10） Krishnan A, Teixeira-Pinto A, Chan D, et al : Impact of early conversion from cyclosporin to everolimus on left ventricular mass index : A randomized controlled trial. Clin Transplant 31, 2017

11） Rousseau B, Guillemin A, Duvoux C, et al : Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer 144 : 886-896, 2019

12） Leeaphorn N, Garg N, Khankin EV, et al : Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens : a retrospective analysis of the UNOS/OPTN database. Transpl Int 31 : 175-186, 2018

13） Blosser CD and Bloom RD : Recurrent glomerular disease after kidney transplantation. Curr Opin Nephrol Hypertens 26 : 501-508, 2017